<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00997828</url>
  </required_header>
  <id_info>
    <org_study_id>2008-0272</org_study_id>
    <nct_id>NCT00997828</nct_id>
  </id_info>
  <brief_title>Bypass Surgery Versus Everolimus-Eluting Stent Implantation for Multivessel Coronary Artery Disease (BEST)</brief_title>
  <acronym>BEST</acronym>
  <official_title>Randomized Comparison of Coronary Artery Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients With Multivessel Coronary Artery Disease (BEST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seung-Jung Park</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>CardioVascular Research Foundation, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CardioVascular Research Foundation, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the safety and efficacy of coronary stent
      implantation using Everolimus-Eluting Coronary Stent System (Abbott, Boston Scientific) is
      not inferior to coronary artery bypass grafting (CABG) for the treatment of patient with
      multivessel coronary artery disease (CAD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary purpose of the BEST Study is to determine whether the safety and efficacy of
      coronary stent implantation using everolimus-eluting balloon expandable stents is not
      inferior to coronary artery bypass grafting for the treatment of multivessel coronary artery
      disease.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 28, 2008</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the composite of death, nonfatal myocardial infarction, and ischemia-driven target vessel revascularization (TVR)</measure>
    <time_frame>at 2 years</time_frame>
    <description>Death includes all cause mortality. MI includes both Q wave and non Q wave, per protocol definition. TVR should be defined by the protocol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the composite of death, myocardial infarction, and any target vessel revascularization</measure>
    <time_frame>at 2years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic MACCE (The composite of death, MI, stroke and ischemia-driven TVR)</measure>
    <time_frame>at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACCE (The composite of death, MI, stroke and any TVR)</measure>
    <time_frame>at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the composite of death, MI, and any TVR</measure>
    <time_frame>at 30 days and yearly to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ischemic MACE(the composite of death, MI, and any TVR)</measure>
    <time_frame>at 30 days and yearly to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACCE (The composite of death, MI, stroke and ischemia-driven TVR)</measure>
    <time_frame>at 30 days and yearly to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ischemic MACCE(The composite of death, MI, stroke and ischemia-driven TVR)</measure>
    <time_frame>at 30 days and yearly to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all cause death</measure>
    <time_frame>at 30 days and yearly to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac death</measure>
    <time_frame>at 30 days and yearly to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocardial infarction</measure>
    <time_frame>at 3o days and yearly to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stroke</measure>
    <time_frame>at 30 days and yearly to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ischemic-driven TVR</measure>
    <time_frame>at 30 days and yearly to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>any target vessel revascularization</measure>
    <time_frame>at 30 days and yearly to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>any target vessel revascularization or target lesion revascularization</measure>
    <time_frame>at 30 days and yearly to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non-target vessel revascularization</measure>
    <time_frame>at 30 days and yearly to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stent thrombosis for the percutaneous coronary intervention arm; acute, subacute, and late</measure>
    <time_frame>at 30 days and yearly to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>analysis segment and in-stent binary restenosis</measure>
    <time_frame>at 9 months angiographic follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>analysis segment and in-stent late loss</measure>
    <time_frame>at 9 months angiographic follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>angina status</measure>
    <time_frame>at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow-up in-stent, in-segment neointimal hyperplasia volume by IVUS</measure>
    <time_frame>at 9 months angiographic follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of stent malapposition, strut fracture, and peri-stent remodeling by IVUS</measure>
    <time_frame>at 9 months angiographic follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft patency in subjects undergoing CABG (defined as: stenosis [DS&gt;50%] in any of the grafts from touch-down to touch-down point)</measure>
    <time_frame>at 9 months angiographic follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac re-hospitalizations</measure>
    <time_frame>at 1 years and yearly to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measurements</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>use of cardiac medications</measure>
    <time_frame>at 1 year and yearly to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dialysis/hemofiltration</measure>
    <time_frame>at 30 days and yearly to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infectious complications</measure>
    <time_frame>at 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of hospitalization related to the target procedure</measure>
    <time_frame>at every event time</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year MACE according to the use of FFR-guided multivessel PCI</measure>
    <time_frame>at 2 years after index procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">888</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>everolimus-eluting stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>everolimus-eluting stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>coronary artery bypass graft surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>coronary artery bypass graft surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>everolimus-eluting stent</intervention_name>
    <description>Xience V stent</description>
    <arm_group_label>everolimus-eluting stent</arm_group_label>
    <other_name>everolimu-eluting stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>coronary artery bypass graft surgery</intervention_name>
    <description>coronary artery bypass graft surgery</description>
    <arm_group_label>coronary artery bypass graft surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years of older

          -  Angiographically confirmed multivessel CAD [critical (&gt;70%) lesions in at least two
             major epicardial vessels and in at least two separate coronary artery territories
             (LAD, LCX, RCA)] and amenable to either PCI or CABG.

          -  Indication for revascularization based upon symptoms of angina and/or objective
             evidence of myocardial ischemia

          -  Geographically accessible and willing to come in for required study visits

          -  Signed informed consent.

        Exclusion Criteria:

          -  Severe congestive heart failure (class III or IV according to NYHA, or pulmonary
             edema) at the time of enrollment.

          -  Planned simultaneous surgical procedure unrelated to coronary revascularization (e.g.
             valve repair/replacement, aneurysmectomy, carotid endarterectomy or carotid stent).

          -  In-stent restenosis of a target vessel

          -  Prior CABG surgery

          -  Prior PCI with stent implantation within 1 year

          -  Two or more chronic total occlusions in major coronary territories

          -  Acute ST-elevation MI(Q-wave) within 72 hours prior to enrollment requiring
             revascularization

          -  Abnormal creatine kinase (CK &gt; 2x normal) and/or abnormal CK-MB levels and/or elevated
             Troponin levels at time of randomization

          -  Previous stroke within 6 months or patients with stroke at more than 6 months with
             significant residual neurologic involvement, as reflected in a Rankin Score &gt; 1

          -  Dementia with a Mini Mental Status Examination (MMSE) score of â‰¤ 20

          -  Extra-cardiac illness that is expected to limit survival to less than 2 years; e.g.
             oxygen-dependent chronic obstructive pulmonary disease, active hepatitis or
             significant hepatic failure, severe renal disease.

          -  Prior history of significant bleeding (within the previous 6 months) that might be
             expected to occur during CABG or PCI/DES related anticoagulation.

          -  Contraindication either CABG or PCI/DES because of a coexisting clinical condition

          -  Significant leucopenia, neutropenia, thrombocytopenia, anemia, or known bleeding
             diathesis

          -  Intolerance or contraindication to aspirin or both clopidogrel and ticlopidine

          -  Suspected pregnancy. A pregnancy test (urine or serum) will be administered
             prerandomization to all women not clearly menopausal

          -  Concurrent enrollment in another clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung-Jung Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangwon National Univ. Hospital</name>
      <address>
        <city>Chuncheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konyang University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Ilsan Paik Hospital</name>
      <address>
        <city>Ilsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Health Insurance Corporation Ilsan Hospital</name>
      <address>
        <city>Ilsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Pusan Paik Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanyang National University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Sanggye Paik Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Yeouido St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.carollo Hospital</name>
      <address>
        <city>Suncheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wonju Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Heart Institue</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarawak General Hospital</name>
      <address>
        <city>Kuching</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Thailand</country>
  </location_countries>
  <removed_countries>
    <country>Hong Kong</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2009</study_first_submitted>
  <study_first_submitted_qc>October 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2009</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>CardioVascular Research Foundation, Korea</investigator_affiliation>
    <investigator_full_name>Seung-Jung Park</investigator_full_name>
    <investigator_title>MD,PhD, Chairman,Heart Institute, Asan Medical Center,University of Ulsan,College of Medicine</investigator_title>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>stent</keyword>
  <keyword>coronary artery bypass graft surgery</keyword>
  <keyword>multivessel coronary artery disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

